- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The World Health Organization (WHO) and UNICEF has issued a joint statement, urging all National TB Programmes to replace the previously used medicines for children weighing less than 25 kg with the child-friendly dispersible TB fixed-dose combinations (FDCs) at the soonest possible time. WHO and UNICEF advise against continued usage of the old sub-optimally dosed FDCs or adult formulations (crushed tablets), which may lead to under or over-dosing, unfavourable treatment outcomes, and high likelihood of contributing to the development of drug resistance.
This document provides a framework for countries to accelerate TB responses among key populations. The framework describes key principles and a process that countries can utilize and adapt to design and implement their TB programmes for key populations. It has been primarily designed for governments and civil society service providers and other stakeholders to take actions against TB among key populations. Other relevant stakeholders include national health coordination bodies and development partners and other implementers that support country efforts to carry out TB services for key populations.
Keywords: TB, treatment, diagnosis, testing
Although it can be prevented and successfully treated, tuberculosis (TB) is the world’s deadliest infectious disease. In Eastern Europe and Central Asia (EECA), conditions are ripe for TB proliferation, with suboptimal TB diagnosis and treatment, poor treatment adherence rates, limited health care in prisons, and high rates of HIV infection and injection drug use, all against a backdrop of weak health care systems. In 2015, most of the 323,000 new TB cases and the 32,000 deaths due to TB in the WHO European Region occurred in EECA. In 2015, an estimated one in five MDR-TB cases globally occurred in the European Region.
The World Health Organization End TB Strategy is fully aligned with the framework of the Sustainable Development Goals (SDGs). Both require due attention to equity, human rights and ethics. In fact, “protecting human rights, ethics and equity” is one of the four key principles of the WHO End TB Strategy. The SDG agenda itself is inspired by a simple motto: “Leave no one behind”. Ensuring that these essential principles guide the implementation of the End TB Strategy is a must, especially when tuberculosis (TB) is rampant among the most vulnerable and marginalized populations everywhere in the world.
The Annual Report of SAARC TB and HIV/AIDS Centre is being presented indicating the programmes, activities and achievements of the year 2016.
Drug-resistant TB is part of the growing challenge of antimicrobial resistant superbugs that do not respond to existing medications, resulting in fewer treatment options and increasing mortality rates for illnesses that would ordinarily be curable — including TB. Global development partners must move faster to contain this threat of antimicrobial resistance before it escalates to claim millions of lives around the world.
UNAIDS calls for the elimination of TB deaths among people living with HIV and for health systems to be strengthened and services integrated to allow for a more rapid scale-up of HIV and TB programming. Countries must expand HIV prevention and treatment programmes that include regular TB screening, preventive therapy and early treatment, since they are simple, affordable and effective programmes that prevent TB deaths.
2016 was a year in which the world faced many major challenges, including disease outbreaks, humanitarian emergencies, and momentous political shifts. The global health community was challenged to ensure the health of the world’s poorest citizens was not forgotten among the headlines. Our task now is to remind the world that investing in health is not an optional luxury, but an essential element to human and economic development.
Keywords: TB, HIV/AIDS, Anti-microbial Resistance (AMR), monitoring, funding
This report is an excellent review of the current status and future plans for the control of TB in the SAARC Region. It includes information on burden of tuberculosis in the SAARC region, including incidence, mortality along with the MDR-TB, TB/HIV confection etc. It also covers the information of the year 2014 and has been prepared on the basis of information collected from member countries during the year 2015 and by reviewing other related documents.
This is the fifteenth Report on Tuberculosis (TB) situation of SAARC Region which is being published by SAARC Tuberculosis and HIV/AIDS Centre (STAC) in a series that started in 2003, which includes a compilation of regional and country-specific achievements, challenges and plans. The main purpose of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic and progress made in TB care and control at Global, SAARC Region and Member States level.